Form 4: Ligand Pharmaceuticals Director Exercises Stock Options

Jason Aryeh, a director at Ligand Pharmaceuticals, exercised non-qualified stock options, acquiring 2,406 shares of common stock at $52.30 on April 30, 2024.

Summary

• On April 30, 2024, Jason Aryeh, a director of Ligand Pharmaceuticals, exercised non-qualified stock options.
• This transaction resulted in the acquisition of 2,406 shares of Ligand Pharmaceuticals' common stock at a price of $52.30 per share.
• Following the transaction, Mr. Aryeh directly owns 76,828 shares and indirectly owns 51,594 shares through certain funds managed by JALAA Equities, LP, JLV Investments, LP and affiliates, and 5,025 shares by Trust.
• The exercised options were previously reported as a grant of 2,754 shares, which vested in full on April 24, 2016, at an exercise price of $89.75 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer.

Sentiment

Score: 5

Explanation: The document is a neutral report of a director exercising stock options. It doesn't inherently convey positive or negative sentiment.

Industry Context

This is a routine disclosure of insider trading activity, which is common for publicly traded companies. It provides transparency into the actions of company directors.

Stakeholder Impact

• The transaction may have a minor impact on shareholders due to the increase in the number of outstanding shares.

Key Dates